bupranolol bupranolol bupranolol is a non-selective beta blocker without intrinsic sympathomimetic activity (isa), but with strong membrane stabilizing activity. its potency is similar to propranolol. bupranololclinical dataahfs/drugs.cominternational drug namesroutes ofadministrationoral, topical (eye drops)atc codec07aa19 (who) pharmacokinetic databioavailability< 10%protein binding76%metabolismfirst pass elimination > 90%elimination half-life2-4 hours (plasma)excretion> 88% renal (as carboxybupranolol)identifiers iupac name (rs)-1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol cas number14556-46-8 npubchem cid2475iuphar/bps550drugbankdb08808 ychemspider2381 yunii858ygi5pitkeggd07590 nchemblchembl305380 ycomptox dashboard (epa)dtxsid7022704 chemical and physical dataformulac14h22clno2molar mass271.79 g·mol−13d model (jsmol)interactive image smiles cc1=cc(=c(c=c1)cl)occ(cnc(c)(c)c)o inchi inchi=1s/c14h22clno2/c1-10-5-6-12(15)13(7-10)18-9-11(17)8-16-14(2,3)4/h5-7,11,16-17h,8-9h2,1-4h3 ykey:hqirnzoqpuahhv-uhfffaoysa-n y ny (what is this?) (verify) uses and dosage like other beta blockers, oral bupranolol can be used to treat hypertension and tachycardia. the initial dose is 50 mg two times a day. it can be increased to 100 mg four times a day. bupranolol eye drops (0.05%-0.5%) are used against glaucoma. pharmacology bupranolol is quickly and completely absorbed from the gut. over 90% undergo first-pass metabolism. bupranolol has a plasma half life of about two to four hours, with levels never reaching 1 µg/l in therapeutic doses. the main metabolite is carboxybupranolol, 4-chloro-3-benzoic acid – that is, the methyl group at the benzene ring is oxidized to a carboxyl group –, of which 88% are eliminated renally within 24 hours. adverse effects, contraindications, interactions adverse effects, contraindications and interactions are similar to other beta blockers.